Mucosal immunization of rhesus macaques with rift valley fever MP-12 vaccine

John C. Morrill, C. J. Peters

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Rhesus macaques given 5 × 104 or 1 × 105 plaque-forming units (pfu) of Rift Valley fever (RVF) MP-12 vaccine by oral, intranasal drops, or small particle aerosol showed no adverse effects up to 56 days after administration. All monkeys given the vaccine by aerosol or intranasal drops developed 80% plaque reduction neutralization titers of ≥ 1:40 by day 21 after inoculation. Only 2 of 4 monkeys given the vaccine by oral instillation developed detectable neutralizing antibodies. All monkeys vaccinated by mucosal routes that developed detectable neutralizing antibodies were protected against viremia when challenged with 1 × 105 pfu of virulent RVF virus delivered by a small particle aerosol at 56 days after vaccination. A single inoculation of the RVF MP-12 live attenuated vaccine by the aerosol or intranasal route may provide an alternative route of protective immunization to RVFV in addition to conventional intramuscular injection.

Original languageEnglish (US)
Pages (from-to)617-625
Number of pages9
JournalJournal of Infectious Diseases
Volume204
Issue number4
DOIs
StatePublished - Aug 15 2011

Fingerprint

Rift Valley Fever
Aerosols
Macaca mulatta
Immunization
Vaccines
Haplorhini
Neutralizing Antibodies
Rift Valley fever virus
Attenuated Vaccines
Viremia
Intramuscular Injections
Vaccination

ASJC Scopus subject areas

  • Infectious Diseases
  • Immunology and Allergy

Cite this

Mucosal immunization of rhesus macaques with rift valley fever MP-12 vaccine. / Morrill, John C.; Peters, C. J.

In: Journal of Infectious Diseases, Vol. 204, No. 4, 15.08.2011, p. 617-625.

Research output: Contribution to journalArticle

Morrill, John C. ; Peters, C. J. / Mucosal immunization of rhesus macaques with rift valley fever MP-12 vaccine. In: Journal of Infectious Diseases. 2011 ; Vol. 204, No. 4. pp. 617-625.
@article{63bc1f0a8ab544f0b7d07580e4c70809,
title = "Mucosal immunization of rhesus macaques with rift valley fever MP-12 vaccine",
abstract = "Rhesus macaques given 5 × 104 or 1 × 105 plaque-forming units (pfu) of Rift Valley fever (RVF) MP-12 vaccine by oral, intranasal drops, or small particle aerosol showed no adverse effects up to 56 days after administration. All monkeys given the vaccine by aerosol or intranasal drops developed 80{\%} plaque reduction neutralization titers of ≥ 1:40 by day 21 after inoculation. Only 2 of 4 monkeys given the vaccine by oral instillation developed detectable neutralizing antibodies. All monkeys vaccinated by mucosal routes that developed detectable neutralizing antibodies were protected against viremia when challenged with 1 × 105 pfu of virulent RVF virus delivered by a small particle aerosol at 56 days after vaccination. A single inoculation of the RVF MP-12 live attenuated vaccine by the aerosol or intranasal route may provide an alternative route of protective immunization to RVFV in addition to conventional intramuscular injection.",
author = "Morrill, {John C.} and Peters, {C. J.}",
year = "2011",
month = "8",
day = "15",
doi = "10.1093/infdis/jir354",
language = "English (US)",
volume = "204",
pages = "617--625",
journal = "Journal of Infectious Diseases",
issn = "0022-1899",
publisher = "Oxford University Press",
number = "4",

}

TY - JOUR

T1 - Mucosal immunization of rhesus macaques with rift valley fever MP-12 vaccine

AU - Morrill, John C.

AU - Peters, C. J.

PY - 2011/8/15

Y1 - 2011/8/15

N2 - Rhesus macaques given 5 × 104 or 1 × 105 plaque-forming units (pfu) of Rift Valley fever (RVF) MP-12 vaccine by oral, intranasal drops, or small particle aerosol showed no adverse effects up to 56 days after administration. All monkeys given the vaccine by aerosol or intranasal drops developed 80% plaque reduction neutralization titers of ≥ 1:40 by day 21 after inoculation. Only 2 of 4 monkeys given the vaccine by oral instillation developed detectable neutralizing antibodies. All monkeys vaccinated by mucosal routes that developed detectable neutralizing antibodies were protected against viremia when challenged with 1 × 105 pfu of virulent RVF virus delivered by a small particle aerosol at 56 days after vaccination. A single inoculation of the RVF MP-12 live attenuated vaccine by the aerosol or intranasal route may provide an alternative route of protective immunization to RVFV in addition to conventional intramuscular injection.

AB - Rhesus macaques given 5 × 104 or 1 × 105 plaque-forming units (pfu) of Rift Valley fever (RVF) MP-12 vaccine by oral, intranasal drops, or small particle aerosol showed no adverse effects up to 56 days after administration. All monkeys given the vaccine by aerosol or intranasal drops developed 80% plaque reduction neutralization titers of ≥ 1:40 by day 21 after inoculation. Only 2 of 4 monkeys given the vaccine by oral instillation developed detectable neutralizing antibodies. All monkeys vaccinated by mucosal routes that developed detectable neutralizing antibodies were protected against viremia when challenged with 1 × 105 pfu of virulent RVF virus delivered by a small particle aerosol at 56 days after vaccination. A single inoculation of the RVF MP-12 live attenuated vaccine by the aerosol or intranasal route may provide an alternative route of protective immunization to RVFV in addition to conventional intramuscular injection.

UR - http://www.scopus.com/inward/record.url?scp=79960850278&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79960850278&partnerID=8YFLogxK

U2 - 10.1093/infdis/jir354

DO - 10.1093/infdis/jir354

M3 - Article

C2 - 21791664

AN - SCOPUS:79960850278

VL - 204

SP - 617

EP - 625

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

SN - 0022-1899

IS - 4

ER -